Breaking News

Sanofi to Acquire Inhibrx Assets for up to $2.2B

Inhibrx's non-101 discovery pipeline will be spun out into a new company, Inhibrx Biosciences, Inc.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi has entered into a definitive agreement under which its subsidiary Aventis Inc. will acquire all assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1 antitrypsin (AAT) augmentation therapy currently in a registrational trial for the treatment of alpha-1 antitrypsin deficiency (AATD).    Inhibrx is a clinical-stage biopharmaceutical company focused on developing biologic therapeutic candidates in oncology and orphan diseases leveraging its protein engineeri...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters